Company Description
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries.
The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus.
It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy.
The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
| Country | NJ |
| Founded | 2019 |
| IPO Date | Nov 1, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 163 |
Contact Details
Address: 103 Carnegie Center Drive, Suite 309 Princeton, New Jersey 08540 United States | |
| Phone | (609) 486-2308 |
Stock Details
| Ticker Symbol | LIANY |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| IPO Price | $16.00 |
| CIK Code | 0001831283 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Konstantin Poukalov | Founder and Executive Chairman |
| Adam Leo Stone | Interim Chief Executive Officer and Director |
| Ehong Gu | Interim Chief Financial Officer, Vice President and Head of Global Finance |
| Ji Chen | Senior Vice President and General Counsel |
| Brianne Jahn | Chief Business Officer |
| Levvy Lv D. Eng | Senior Vice President and Global Head of Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 21, 2024 | 15-12G | Securities registration termination |
| Mar 12, 2024 | EFFECT | Notice of Effectiveness |
| Mar 12, 2024 | F-6 POS | Post-effective amendments for immediately effective filing |
| Mar 12, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Mar 12, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Mar 12, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Mar 12, 2024 | POS AM | Post-Effective amendments for registration statement |
| Mar 11, 2024 | 25 | Filing |
| Feb 29, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 13, 2024 | 8-K | Current Report |